News | 09 August 2012
Ranbaxy's ability to launch the Lipitor generic had been doubted, as the US Food and Drug Administration (US FDA) had alleged the company had violated manufacturing practices in the last few years. Products from Ranbaxy's key facilities like Dewas and ...
Click on the link to read the full article at Business Standard
(This link will open in a new window)